Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1633 1634 1645
This examiner grants 55% of resolved cases
Maria Marvich is an experienced examiner in Tech Center 1600 and Art Unit 1631, having overseen 988 resolved cases. The examiner's allowance rate of 54.9 percent reflects a balanced approach to patentability. However, the prosecution timeline is notably long, with a median days to allowance of 1471, suggesting that reaching a final resolution requires significant persistence. The 988 resolved cases provide a high degree of statistical reliability for these metrics.
The data reveals a strong interview lift of 28.1 percent, indicating that interviews are a vital component of a successful prosecution strategy. This lift suggests that verbal communication often helps resolve issues that might otherwise stall in written exchanges. With a large volume of resolved cases, these metrics are well-established. Applicants should anticipate a process that may span 1471 days but can be significantly improved by leveraging the 28.1 percent lift associated with examiner interviews. The 54.9 percent allowance rate underscores the importance of this tactical engagement.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18545113 | ONCOLYTIC VIRUS AND USES THEREOF | Non-Final OA | Janssen Biotech, Inc. |
| 19406703 | LIVER DETARGETED CAPSIDS | Non-Final OA | KATE THERAPEUTICS, INC. |
| 17767970 | CANINE DISTEMPER VIRUS HEMAGGLUTININ AND FUSION POLYPEPTIDES | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17768591 | COMPOSITIONS AND METHODS FOR USING ALTERNATIVE SPLICING TO CONTROL SPECIFICITY OF GENE THERAPY | Final Rejection | The Johns Hopkins University |
| 18019423 | Molecular Targets for Modulation of Dissociative and Associative States | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 19355982 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | Non-Final OA | Massachusetts Institute of Technology |
| 17353587 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | Final Rejection | Board of Regents of The University of Texas System |
| 18050192 | Compositions and Methods for Treating Cancer with TSLPR-CD19 or TSLPR-CD22 Immunotherapy | Non-Final OA | The Regents of the University of Colorado |
| 18875094 | CAR-EXPRESSING PLURIPOTENT STEM CELL-DERIVED NEUTROPHILS LOADED WITH DRUG NANOPARTICLES AND USES THEREOF | Non-Final OA | Purdue Research Foundation |
| 17813843 | COMPOSITIONS AND METHODS FOR DECREASING TAU EXPRESSION | Non-Final OA | Novartis AG |
| 18847004 | DELIVERY METHODS USING PLATELETS | Non-Final OA | Children's Hospital Medical Center |
| 18748156 | HYPOVENTILATION PHYSICAL MODELS AND APPLICATIONS THEREOF | Non-Final OA | The University of Hong Kong |
| 17855322 | ADENOVIRAL- BASED BIOLOGICAL DELIVERY AND EXPRESSION SYSTEM FOR USE IN THE TREATMENT OF OSTEOARTHRITIS | Non-Final OA | Baylor College of Medicine |
| 17839667 | MICROFLUIDIC DEVICE FOR ANALYZING GENE EXPRESSION | Final Rejection | Yeda Research and Development Co. Ltd. |
| 17694841 | Viral Vectors for Prophylaxis and Therapy of Hemoglobinopathies | Non-Final OA | The Children's Hospital of Philadelphia |
| 18074107 | TARGETING BCL11A DISTAL REGULATORY ELEMENTS FOR FETAL HEMOGLOBIN REINDUCTION | Non-Final OA | The Children's Medical Center Corporation |
| 18556163 | METHODS AND MEANS FOR THE PREVENTION AND/OR TREATMENT OF HEMOPHILIC ARTHROPATHY IN HEMOPHILIA | Final Rejection | UNIQURE BIOPHARMA B.V. |
| 18054063 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A CAMPTOTHECIN MOIETY | Final Rejection | Tubulis GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy